Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Net Income towards Common Stockholders (2016 - 2025)

Guided Therapeutics' Net Income towards Common Stockholders history spans 15 years, with the latest figure at -$785000.0 for Q3 2025.

  • For Q3 2025, Net Income towards Common Stockholders fell 13.44% year-over-year to -$785000.0; the TTM value through Sep 2025 reached -$654000.0, up 72.29%, while the annual FY2024 figure was -$441000.0, 88.27% up from the prior year.
  • Net Income towards Common Stockholders for Q3 2025 was -$785000.0 at Guided Therapeutics, up from -$856000.0 in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $1.4 million in Q4 2024 and bottomed at -$1.9 million in Q4 2022.
  • The 5-year median for Net Income towards Common Stockholders is -$758000.0 (2024), against an average of -$721421.1.
  • The largest annual shift saw Net Income towards Common Stockholders crashed 1964.71% in 2022 before it soared 409.17% in 2024.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$509000.0 in 2021, then crashed by 264.83% to -$1.9 million in 2022, then skyrocketed by 74.74% to -$469000.0 in 2023, then skyrocketed by 409.17% to $1.4 million in 2024, then crashed by 154.14% to -$785000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Net Income towards Common Stockholders are -$785000.0 (Q3 2025), -$856000.0 (Q2 2025), and -$463000.0 (Q1 2025).